Reuters logo
BRIEF-Daiichi Sankyo announces enliven Phase 3 study of Pexidartinib met primary endpoint in Tenosynovial giant cell tumor​
2017年10月31日 / 凌晨4点07分 / 25 天前

BRIEF-Daiichi Sankyo announces enliven Phase 3 study of Pexidartinib met primary endpoint in Tenosynovial giant cell tumor​

Oct 31 (Reuters) - Daiichi Sankyo Co Ltd

* ‍Daiichi Sankyo announces enliven Phase 3 study of Pexidartinib met primary endpoint in Tenosynovial giant cell tumor​ Source text for Eikon: Further company coverage:

我们的标准:汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below